N/A N=102 A Prospective Study of Human Bone Adaptation Using a Novel in Vivo Loading Model
Bone Loss
Primary: Change in UD iBMC — 0.0049; -0.0020; 0.0252; 0.0309 g — p=0.119
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=22 Bone Augmentation Techniques in Extraction Sockets
Tooth Loss
Primary: Changes in Hard Tissue Composition — 35.82; 31.76 mm
N/A N=9 Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
N/A N=90 Exploration of Blood Flow Regulation to Bone in Humans
Bone Blood Flow Regulation
Primary: Tibial Blood Perfusion — 0.54; -1.47; 0.43; 2.08 μM (concentration)
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
N/A N=44 Blood Flow and Bone Density in Healthy Adult Women
Bone Loss · Hypotensive · Lower Limb Fluid Pooling
Primary: Bone Density of Proximal Femur — -0.133; -.675; 1.3 percent change in bone density
N/A N=37 The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges
Alveolar Ridge Augmentation · Alveolar Ridge Preservation
Primary: New Bone Formation (in %) With the Use of Small vs. Large Particle Bone Allografts — 17.3; 25.9; 41.0; 31.4 % of new bone
Phase 4 N=34 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
Postmenopausal Osteoporosis
Primary: Cancellous Bone Formation Rate at Month 3 — 0.13; 0.01; 0.06 mm3/mm2/day
Phase 4 N=210 Bone and Body Comp: A Sub Study of the SECOND-LINE Study
HIV
Primary: Mean Bone Mineral Density Changes From Baseline to 48 Weeks as Measured by DXA Scan — -5.2; -2.9 percentage change
Phase 2 N=26 Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3
Phase 3 N=161 Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
Osteopenia
Primary: Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12 — -1.486; -1.255 Percent Change — p=0.7096
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 2 N=17 Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: BMD of Total Hip by DXA — 1.32 Percent change
Phase 2 N=22 Bone Material Comparison in Maxillary Sinus Augmentation
Alveolar Bone Resorption · Sequela · Tooth Extrusion
Primary: Bone Density - Limited View CBCT (Cone-beam Computed Tomography) Measurements — 14.4; 1.5 percentage of bone height shrinkage
N/A N=9 A Histomorphometric Analysis Following Sinus Augmentation Using Two Different Bone Graft Materials.
Missing Teeth
Primary: Percentage of New Vital Bone. — 16.33; 26.11; 30.5; 39.67 percentage of new vital bone
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Phase 2 N=63 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
HIV Infection · Bone Loss · Osteopenia
Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml
Phase 2 N=61 Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: Bone Mineral Density BMD of the Total Hip as Assessed by DXA. — 0.66; 0.63; 0.64; 0.65 g/cm^2 — p=0.84
Phase 4 N=26 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
Osteoporosis
Primary: Serum Markers of Skeletal Turnover (Serum CTX) — 0.9887; 0.5445 ng/mL
N/A N=12 Effect of High Doses of Radiation on Bone Structure and Metabolism
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3